ArticleERJ open research2020

An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CF

Christopher H Goss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.